Natera is a diagnostics & research business based in the US. Natera shares (NTRA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $155.50 – an increase of 3.03% over the previous week. Natera employs 4,424 staff and has a trailing 12-month revenue of around $1.7 billion.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $155.50 |
|---|---|
| 52-week range | $92.14 - $183.00 |
| 50-day moving average | $148.05 |
| 200-day moving average | $142.14 |
| Wall St. target price | $187.72 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.53 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $157.38 from 2025-05-05
| 1 week (2025-04-29) | 1.61% |
|---|---|
| 1 month (2025-04-07) | 13.83% |
| 3 months (2025-02-07) | -8.93% |
| 6 months (2024-11-07) | 20.70% |
| 1 year (2024-05-07) | 62.00% |
|---|---|
| 2 years (2023-05-05) | 190.91% |
| 3 years (2022-05-06) | 336.20% |
| 5 years (2020-05-07) | 261.71% |
| Revenue TTM | $1.7 billion |
|---|---|
| Gross profit TTM | $1 billion |
| Return on assets TTM | -8.96% |
| Return on equity TTM | -19.42% |
| Profit margin | -11.22% |
| Book value | $9.01 |
| Market Capitalization | $20.6 billion |
TTM: trailing 12 months
We're not expecting Natera to pay a dividend over the next 12 months.
Over the last 12 months, Natera's shares have ranged in value from as little as $92.14 up to $183. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Natera's is 1.801. This would suggest that Natera's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Natera, Inc. , a diagnostics company, provides molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera molecular residual disease test for assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based genomic profiling test, that provides insight into genomic alterations and biomarkers; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product. It serves independent laboratories, national and regional reference laboratories, medical centers and physician practices, research laboratories, and pharmaceutical companies through its direct sales force, and a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co.